{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-018762","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.978387+00:00","generated_at":"2026-06-21T03:28:22.101701+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Olema Pharmaceuticals amends bylaws to update stockholder nomination procedures","bullets":["Board approved amended and restated bylaws effective December 15, 2022.","Revisions address Rule 14a-19 universal proxy rules and update director nomination information requirements.","Updated provisions on conduct of stockholder meetings and setting date, time, place."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-018762","json":"https://secwatch.observer/filing/0001558370-22-018762.json","markdown":"https://secwatch.observer/filing/0001558370-22-018762.md","text":"https://secwatch.observer/filing/0001558370-22-018762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837022018762/0001558370-22-018762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837022018762/olma-20221215x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:28:22.101701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02b47be122ae5fe4eb4a1fac990bc49357e78755","claim":"Olema Pharmaceuticals, Inc.: Amended and restated bylaws to update procedures for stockholder nominations regarding Rule 14a-19, update information requirements for director nominations and other business proposals, and update provisions for stockholder meetings (effective 2022-12-15).","evidence_excerpt":"On December 15, 2022, the Board of Directors (the “ Board ”) of Olema Pharmaceuticals, Inc. (the “ Company ”) approved the amendment and restatement of the Bylaws of the Company (the “ Amended and Restated Bylaws ”). The Amended and Restated Bylaws are effective as of December 15, 2022.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837022018762/0001558370-22-018762-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-15"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}